Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
The Motley Fool January 12, 2010 Brian Orelli	Swine Flu: The Side Dish That Couldn't Last More governments canceling vaccine-purchasing contracts. The sky is falling on swine-flu-vaccine makers.
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
AskMen.com Jacob Franek	Swine Flu: The Good, The Bad And The Ugly Here is a short list of what we do and don't know of swine flu.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
AskMen.com Jacob Franek	Swine Flu Update With the fall flu season rapidly approaching, a swine flu update is warranted.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool July 29, 2009 Brian Orelli	The Swine Flu Can't Save Sanofi No shocker there.
BusinessWeek February 4, 2010 Weintraub et al.	Swine Flu: The Pandemic That Wasn't Swine flu is waning, but the lessons of H1N1 could come in handy during a more serious epidemic.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
AskMen.com	Swine Flu: The Game Dutch researchers have created a free, online-only game that challenges players to control a new pandemic -- swine flu.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool November 30, 2006 Brian Lawler	Happy (Sniffle) Holidays (Cough) It's flu season again, and the market for influenza vaccines is hot. Pharma investors, take note.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
Chemistry World January 22, 2013 Andrew Turley	Flu vaccine without the eggs approved Flublok from US biotech Protein Sciences has become the first flu vaccine made using an insect virus to win marketing approval in the US.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool June 15, 2007 Brian Orelli	Get Your Uncle to Pay for Your Capital Improvements MedImmune and Sanofi-Aventis recently announced that they had convinced the U.S. government to pick up a majority of the tabs to renovate their plants. There aren't too many industries where you can invest in companies that get free money from the government.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
BusinessWeek November 28, 2005 Kerry Capell	High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally.
AskMen.com	1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
The Motley Fool December 13, 2011 Frank Vinluan	N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic.
AskMen.com	Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool November 30, 2005 Brian Gorman	Is BioCryst For Real? Investors may have been right about BioCryst, but for the wrong reasons. Investors were clearly betting a lot on a drug that is still in early phase testing and had failed in the past.
The Motley Fool March 30, 2006 David Compton	Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
American Family Physician January 15, 2004	Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc.
The Motley Fool April 29, 2010 Brian Orelli	Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool October 26, 2011 Chris Baines	Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies.
Bank Systems & Technology December 1, 2005 Katherine Burger	Calling in Sick There may be a kind of disaster looming that even the most recovery-savvy businesses have not anticipated -- a major flu outbreak. The implications regarding business continuity plans are as serious as a looming hurricane.
Health October 2007 Sarah Clachar	Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.